

Fidaxomicin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
3.8	09/30/2023	1732000-00013	Date of first issue: 06/05/2017

SECTION 1. IDENTIFICATION

Product name : Fidaxomicin Formulation
Other means of identification : No data available

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc
Address : 126 E. Lincoln Avenue
Rahway, New Jersey U.S.A. 07065
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical
Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the Hazardous Products Regulations

Acute toxicity (Oral) : Category 4

GHS label elements

Hazard pictograms :



Signal Word : Warning

Hazard Statements : H302 Harmful if swallowed.

Precautionary Statements :

Prevention:
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.

Response:
P301 + P312 + P330 IF SWALLOWED: Call a doctor if you feel unwell. Rinse mouth.

Disposal:
P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Fidaxomicin Formulation

Version 3.8 Revision Date: 09/30/2023 SDS Number: 1732000-00013 Date of last issue: 04/04/2023
Date of first issue: 06/05/2017

Substance / Mixture : Mixture

Components

Chemical name	Common Name/Synonym	CAS-No.	Concentration (% w/w)
Fidaxomicin	No data available	873857-62-6	$\geq 40 - \leq 60$
Cellulose	No data available	9004-34-6	$\geq 15 - \leq 30$
Starch	Sago starch	9005-25-8	$\geq 5 - \leq 15$

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap as a precaution.
Get medical attention if symptoms occur.

In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting unless directed to do so by medical personnel.
Get medical attention.
Rinse mouth thoroughly with water.
Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and delayed : Harmful if swallowed.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.

Fidaxomicin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
3.8	09/30/2023	1732000-00013	Date of first issue: 06/05/2017

Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.
Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labeled containers.
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type	Control parame-	Basis
------------	---------	------------	-----------------	-------

Fidaxomicin Formulation

Version 3.8 Revision Date: 09/30/2023 SDS Number: 1732000-00013 Date of last issue: 04/04/2023
Date of first issue: 06/05/2017

		(Form of exposure)	ters / Permissible concentration	
Fidaxomicin	873857-62-6	TWA	200 µg/m ³ (OEB 2)	Internal
Cellulose	9004-34-6	TWA	10 mg/m ³	CA AB OEL
		TWA (Total dust)	10 mg/m ³	CA BC OEL
		TWA (respirable dust fraction)	3 mg/m ³	CA BC OEL
		TWAEV (total dust)	10 mg/m ³	CA QC OEL
		TWA	10 mg/m ³	ACGIH
Starch	9005-25-8	TWA	10 mg/m ³	CA AB OEL
		TWA (Total dust)	10 mg/m ³	CA BC OEL
		TWA (respirable dust fraction)	3 mg/m ³	CA BC OEL
		TWAEV (total dust)	10 mg/m ³	CA QC OEL
		TWA	10 mg/m ³	ACGIH

Engineering measures : Ensure adequate ventilation, especially in confined areas.
Minimize workplace exposure concentrations.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending on the concentration specific to place of work. Breakthrough time is not determined for the product. Change gloves often!
For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Eye protection : Wear the following personal protective equipment:
Safety glasses

Skin and body protection : Skin should be washed after contact.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Fidaxomicin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
3.8	09/30/2023	1732000-00013	Date of first issue: 06/05/2017

Appearance	:	solid
Color	:	white to off-white
Odor	:	No data available
Odor Threshold	:	No data available
pH	:	Not applicable
Melting point/freezing point	:	175 - 185 °C Active ingredient
Initial boiling point and boiling range	:	Not applicable
Flash point	:	Not applicable
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not classified as a flammability hazard
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	log Pow: 4.4 Active ingredient
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

Fidaxomicin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
3.8	09/30/2023	1732000-00013	Date of first issue: 06/05/2017

Molecular weight : Not applicable

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Can react with strong oxidizing agents.

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Skin contact

Ingestion

Eye contact

Acute toxicity

Harmful if swallowed.

Product:

Acute oral toxicity : Acute toxicity estimate: 833.33 mg/kg
Method: Calculation method

Components:

Fidaxomicin:

Acute oral toxicity : LD50 (Rat): > 1,000 mg/kg
LD50 (Dog): > 120 mg/kg

Acute toxicity (other routes of administration) : LD50 (Rat): 200 mg/kg
Application Route: Intravenous

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Starch:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Fidaxomicin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
3.8	09/30/2023	1732000-00013	Date of first issue: 06/05/2017

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Starch:

Species	:	Rabbit
Result	:	No eye irritation

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Starch:

Test Type	:	Maximization Test
Routes of exposure	:	Skin contact
Species	:	Guinea pig
Result	:	negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Fidaxomicin:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
-----------------------	---	--

Test Type: Chromosome aberration test in vitro
Test system: Chinese hamster ovary cells
Result: positive

Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Rat Application Route: Intravenous Result: negative
----------------------	---	--

Test Type: comet assay
Species: Rat
Result: negative

Fidaxomicin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
3.8	09/30/2023	1732000-00013	Date of first issue: 06/05/2017

Cellulose:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: In vitro mammalian cell gene mutation test Result: negative
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Ingestion Result: negative

Starch:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
-----------------------	---	--

Carcinogenicity

Not classified based on available information.

Components:

Cellulose:

Species	:	Rat
Application Route	:	Ingestion
Exposure time	:	72 weeks
Result	:	negative

Reproductive toxicity

Not classified based on available information.

Components:

Fidaxomicin:

Effects on fertility	:	Test Type: Fertility/early embryonic development Species: Rat Application Route: Intravenous injection Fertility: NOAEL: 6.3 mg/kg body weight
Effects on fetal development	:	Test Type: Embryo-fetal development Species: Rat Application Route: Intravenous injection Developmental Toxicity: NOAEL: 12.6 mg/kg body weight Remarks: No significant adverse effects were reported
		Test Type: Embryo-fetal development Species: Rabbit Application Route: Intravenous injection Developmental Toxicity: NOAEL: 7 mg/kg body weight Remarks: No significant adverse effects were reported

Cellulose:

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Fidaxomicin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
3.8	09/30/2023	1732000-00013	Date of first issue: 06/05/2017

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

Fidaxomicin:

Species : Rat
NOAEL : 90 mg/kg
Application Route : Oral
Exposure time : 28 D
Remarks : No significant adverse effects were reported

Species : Rat
NOAEL : 62.5 mg/kg
Application Route : Intravenous
Exposure time : 14 D

Species : Dog
NOAEL : 9,600 mg/kg
Application Route : Oral
Exposure time : 3 M
Symptoms : Vomiting
Remarks : No significant adverse effects were reported

Species : Monkey
NOAEL : 90 mg/kg
Application Route : Oral
Exposure time : 28 D
Remarks : No significant adverse effects were reported

Species : Juvenile rat
NOAEL : 200 mg/kg
Application Route : Oral
Exposure time : 28 D
Remarks : No significant adverse effects were reported

Cellulose:

Species : Rat

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Fidaxomicin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
3.8	09/30/2023	1732000-00013	Date of first issue: 06/05/2017

NOAEL : $\geq 9,000$ mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Starch:

Species : Rat
NOAEL : $\geq 2,000$ mg/kg
Application Route : Skin contact
Exposure time : 28 Days
Method : OECD Test Guideline 410

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Fidaxomicin:

Ingestion : Symptoms: Abdominal pain, Nausea, Vomiting, constipation

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Fidaxomicin:

Toxicity to algae/aquatic plants : EC50 (Anabaena flos-aquae (cyanobacterium)): > 18.4 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

NOEC (Anabaena flos-aquae (cyanobacterium)): 5.8 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 8.91 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 19.6 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 50 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 5.9 mg/l

Fidaxomicin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
3.8	09/30/2023	1732000-00013	Date of first issue: 06/05/2017

Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Cellulose:

Toxicity to fish : LC50 (*Oryzias latipes* (Japanese medaka)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

Persistence and degradability

Components:

Cellulose:

Biodegradability : Result: Readily biodegradable.

Bioaccumulative potential

Components:

Fidaxomicin:

Partition coefficient: n-octanol/water : log Pow: 4.4

Mobility in soil

Components:

Fidaxomicin:

Distribution among environmental compartments : log Koc: 0.80

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Fidaxomicin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
3.8	09/30/2023	1732000-00013	Date of first issue: 06/05/2017

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

TDG

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
CA AB OEL	:	Canada. Alberta, Occupational Health and Safety Code (table 2: OEL)
CA BC OEL	:	Canada. British Columbia OEL
CA QC OEL	:	Québec. Regulation respecting occupational health and safety, Schedule 1, Part 1: Permissible exposure values for airborne contaminants
ACGIH / TWA	:	8-hour, time-weighted average
CA AB OEL / TWA	:	8-hour Occupational exposure limit
CA BC OEL / TWA	:	8-hour time weighted average
CA QC OEL / TWA EV	:	Time-weighted average exposure value

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Or-

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Fidaxomicin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
3.8	09/30/2023	1732000-00013	Date of first issue: 06/05/2017

ganisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 09/30/2023
Date format : mm/dd/yyyy

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8